Burning Rock Dx is a biotechnology company that specializes in precision medicine solutions and diagnostics for oncology patients. Our expertise in novel NGS technology, strategic partnerships with other leading biotechnology companies in the industry, and the team of over 900 specialists uniquely position us to lead the charge towards individualized patient care.
We are working to establish a global network of CLIA/CAP labs to simplify the process of running concurrent trials in different countries and improving data comparability across regions. In combination with our IVD kit capability and cGMP manufacturing, this global perspective lends itself towards standardization, collaboration, and concurrence across sites. We currently operate 3 labs. A CLIA/CAP lab in Guangzhou with NGS and IHC capability, a CLIA/CAP lab in Irvine, CA with NGS, IHC, and R&D capability, and a lab in Shanghai with R&D and NGS capability.
Burning Rock Dx offers a variety of DNA and RNA NGS panels across numerous cancer types including breast, GI, Lung, Prostate, Lymphoma, Thyroid, and Pan cancers. We offer our partners true flexibility in testing with the capability of developing custom assays and utilizing multiple sample sources including plasma, FFPE, and white buffy coat.